Rebecca A. Gardner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rebecca A. Gardner has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Assaf P. Oron
Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, WA
1 shared publication- Atif Bhatti
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA
1 shared publication - Cameron J. Turtle
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, USA
1 shared publication Catherine Lindgren
Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA
1 shared publicationChristopher Brown
Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA
1 shared publication- Christopher D. Blosser
University of Washington, Seattle, WA, USA
1 shared publication
Latest Publications
- Open Access
- 12 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (3) , 416-422
Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy
- 12 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (3) , 416-422
Open AccessAnti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy
- Top Cited Papers
- 22 June 2017
- Published by American Society of Hematology in Blood
- Vol. 129 (25) , 3322-3331
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Transitioning CD19-directed chimeric antigen receptor (CAR) T cells from early-phase trials in relapsed patients to a viable therapeutic approach with predictable efficacy and low toxicity for broad application among patients with high unmet need is currently complicated by product heterogeneity resulting from transduction of undefined T-cell mixtures, variability of transgene expression, and terminal differentiation of cells at the end of culture. A phase 1 trial of 45 children and young adults with relapsed or refractory B-lineage acute lymphoblastic leukemia was conducted using a CD19 CAR product of defined CD4/CD8 composition, uniform CAR expression, and limited effector differentiation. Products meeting all defined specifications occurred in 93% of enrolled patients. The maximum tolerated dose was 106 CAR T cells per kg, and there were no deaths or instances of cerebral edema attributable to product toxicity. The overall intent-to-treat minimal residual disease–negative (MRD−) remission rate for this phase 1 study was 89%. The MRD− remission rate was 93% in patients who received a CAR T-cell product and 100% in the subset of patients who received fludarabine and cyclophosphamide lymphodepletion. Twenty-three percent of patients developed reversible severe cytokine release syndrome and/or reversible severe neurotoxicity. These data demonstrate that manufacturing a defined-composition CD19 CAR T cell identifies an optimal cell dose with highly potent antitumor activity and a tolerable adverse effect profile in a cohort of patients with an otherwise poor prognosis. This trial was registered at www.clinicaltrials.gov as #NCT02028455. Publisher9s Note: There is an Inside Blood Commentary on this article in this issue. Key Points Defined-composition manufacturing platform of CD19 CAR T cells contributes to >90% intent-to-treat complete remission rate. Uniformity of durable persistence of CAR T cells and mitigation of antigen escape are key aspects for further optimization.
- 22 June 2017
- Published by American Society of Hematology in Blood
- Vol. 129 (25) , 3322-3331
Top Cited PapersIntent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Transitioning CD19-directed chimeric antigen receptor (CAR) T cells from early-phase trials in relapsed patients to a viable therapeutic approach with predictable efficacy and low toxicity for broad application among patients with high unmet need is currently complicated by product heterogeneity resulting from transduction of undefined T-cell mixtures, variability of transgene expression, and terminal differentiation of cells at the end of culture. A phase 1 trial of 45 children and young adults with relapsed or refractory B-lineage acute lymphoblastic leukemia was conducted using a CD19 CAR product of defined CD4/CD8 composition, uniform CAR expression, and limited effector differentiation. Products meeting all defined specifications occurred in 93% of enrolled patients. The maximum tolerated dose was 106 CAR T cells per kg, and there were no deaths or instances of cerebral edema attributable to product toxicity. The overall intent-to-treat minimal residual disease–negative (MRD−) remission rate for this phase 1 study was 89%. The MRD− remission rate was 93% in patients who received a CAR T-cell product and 100% in the subset of patients who received fludarabine and cyclophosphamide lymphodepletion. Twenty-three percent of patients developed reversible severe cytokine release syndrome and/or reversible severe neurotoxicity. These data demonstrate that manufacturing a defined-composition CD19 CAR T cell identifies an optimal cell dose with highly potent antitumor activity and a tolerable adverse effect profile in a cohort of patients with an otherwise poor prognosis. This trial was registered at www.clinicaltrials.gov as #NCT02028455. Publisher9s Note: There is an Inside Blood Commentary on this article in this issue. Key Points Defined-composition manufacturing platform of CD19 CAR T cells contributes to >90% intent-to-treat complete remission rate. Uniformity of durable persistence of CAR T cells and mitigation of antigen escape are key aspects for further optimization.